Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 226, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.113851
Keywords
Cancer; beta-glucuronidase; Bioconjugation; Albumin; Camptothecin
Categories
Funding
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China [22077034]
Ask authors/readers for more resources
The study presented an albumin-based drug delivery system, synthesized an antitumor prodrug Mal-glu-CPTS0001, and demonstrated its in vivo antitumor effects. The prodrug covalently binds to plasma albumin, releases the drug in tumors, and achieves reduced toxicity and enhanced selectivity.
The albumin-based drug delivery system is an effective drug delivery strategy for traditional chemotherapeutic drugs that can improve their antitumour efficacies and reduce systemic toxicities. The camptothecin derivative CPTS0001 has excellent antitumour activity in vitro, but it shows toxicity and side effects in vivo. In this study, we report the synthesis and biological evaluation of the beta-glucuronidase-reactive albumin-binding prodrug Mal-glu-CPTS0001 based on quaternary ammonium. After intravenous administration, the compound covalently binds to plasma albumin through Michael addition, enabling it to accumulate in tumours, where tumour-associated beta-glucuronidase triggers the selective release of CPTS0001. This prodrug significantly reduced the toxicity of the parent drug, and the maximum tolerated dose was increased by 2.5 times. At the same time, this prodrug enhanced the selectivity in vivo and improved the preferential accumulation of prodrug in tumours. Notably, this prodrug exhibited excellent in vivo antitumour effects in a murine breast cancer xenograft model without visible pathological toxicity. (C) 2021 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available